Top

BMC Ophthalmology

Published in:

Open Access 01-12-2020 | Diabetic Retinopathy | Research article

The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study

Authors: Tingting Jiang, Junxiang Gu, Peijun Zhang, Wenwen Chen, Qing Chang

Published in: BMC Ophthalmology | Issue 1/2020

Abstract

Background

To investigate the effect of intravitreal conbercept (IVC) injections on the incidence of postoperative vitreous hemorrhage (VH) in eyes undergoing surgery for severe proliferative diabetic retinopathy.

Methods

This was a pilot prospective, comparative, and randomized study. Thirty patients, who underwent vitrectomy for severe proliferative diabetic retinopathy, were assigned randomly to either group 1 (intravitreal conbercept [IVC] injection at the end of pars plana vitrectomy) or group 2 (no IVC injection). Postoperative follow-up was performed on the first day, first week, first month, third month, sixth month and first year after surgery. The primary outcome was the incidence of postoperative VH. Secondary outcomes were the initial time of vitreous clearing (ITVC), best-corrected visual acuity (BCVA) and central retinal thickness (CRT) after surgery.

Results

A total of 30 eyes, from 30 patients, were included. Fifteen eyes were enrolled in the IVC group and fifteen in the control group. The incidence of early and late postoperative VH was not significantly different between the control and IVC groups. ITVC was shorter in the IVC group than that in the control group, but this was not significant (7.38 ± 10.66 vs 13.23 ± 17.35, P = 0.31). Final BCVA, 1 year after surgery, showed significant improvement compared to baseline in both groups. However, analysis of the BCVA at any postoperative visit after surgery showed no significant differences between the two groups. There were two cases of recurrent VH identified at 3 and 6 months after surgery in each group, requiring a second round of surgery. Foveal thickness was significantly different between the two groups at the 3-month, 6-month and 1-year follow-up visits.

Conclusions

In this pilot study, the effect of IVC injection in reducing the incidence of postoperative VH after diabetic vitrectomy at the end of vitrectomy was not shown.

Trial registration

The study was registered with the Chinese Clinical Trial Registry. (Reference Number: ChiCTR1800015751).

Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology. 1983;90(5):522–30.CrossRefPubMed

de Bustros S, Glaser BM, Michels RG, Auer C. Effect of epsilon-aminocaproic acid on postvitrectomy haemorrhage. Arch Ophthalmol. 1985;103(2):219–21.CrossRefPubMed

Ramezani AR, Ahmadieh H, Ghaseminejad AK, Yazdani S, Golestan B. Effect of tranexamic acid on early post-vitrectomy diabetic haemorrhage: a randomized clinical trial. Br J Ophthalmol. 2005;89(8):1041–4. https://doi.org/10.1136/bjo.2004.062638.CrossRefPubMedPubMedCentral

Joondeph BC, Blankenship GW. Haemostatic effects of air versus fluid in diabetic vitrectomy. Ophthalmol. 1989;96(12):1701–6.CrossRef

Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ, Parikakis EA, Theodossiadis GP. Haemostatic effects of SF6 after diabetic vitrectomy for vitreous haemorrhage. Acta Ophthalmol Scand. 2001;79(1):34–8.CrossRefPubMed

Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26(6):699–700. https://doi.org/10.1097/01.iae.0000225351.87205.69.CrossRefPubMed

Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1–15. https://doi.org/10.1016/j.ophtha.2006.05.064.CrossRefPubMed

Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol. 2018;102(8):1077–85. https://doi.org/10.1136/bjophthalmol-2017-311344.CrossRefPubMed

Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118(11):2218–26. https://doi.org/10.1016/j.ophtha.2011.03.036.CrossRefPubMed

10.

Park DH, Shin JP, Kim SY. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):641–50. https://doi.org/10.1007/s00417-009-1247-7.CrossRefPubMed

11.

Cheema RA, Mushtaq J, Al-Khars W, Al-Askar E, Cheema MA. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina. 2010;30(10):1646–50. https://doi.org/10.1097/IAE.0b013e3181d6def0.CrossRefPubMed

12.

Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H. Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? Eur J Ophthalmol. 2009;19(4):618–21.CrossRefPubMed

13.

Jirawison C, Ittipunkul N. Intravitreal Bevacizumab at the end of diabetic-Vitrectomy for prevention of postoperative vitreous hemorrhage: a comparative study. J Med Assoc Thail. 2012;95(Suppl 4):S136–42.

14.

Göncü T, Özdek S, Ünlü M. The role of intraoperative bevacizumab for prevention of postoperative vitreous hemorrhage in diabetic vitreous hemorrhage. Eur J Ophthalmol. 2014;24(1):88–93. https://doi.org/10.5301/ejo.5000327.CrossRefPubMed

15.

Yang X, Xu J, Wang R, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy. J Ophthalmol. 2016;2016:2473234. https://doi.org/10.1155/2016/2473234.CrossRefPubMedPubMedCentral

16.

Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91(12):1485–9.CrossRefPubMed

17.

Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989;96(10):1495–500.CrossRefPubMed

18.

Hershberger VS, Augsburger JJ, Hutchins RK, Raymond LA, Krug S. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology. 2004;111(6):1215–21. https://doi.org/10.1016/j.ophtha.2003.08.043.CrossRefPubMed

19.

Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol. 2006;90(6):697–701. https://doi.org/10.1136/bjo.2005.087403.CrossRefPubMedPubMedCentral

20.

Sadiq SA, Chatterjee A, Vernon SA. Progression of diabetic retinopathy and rubeotic glaucoma following cataract surgery. Eye. 1995;9(Pt 6):728–38. https://doi.org/10.1038/eye.1995.185.CrossRefPubMed

21.

Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):147–63. https://doi.org/10.1007/s00417-008-0980-7.CrossRefPubMed

22.

Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71–98.CrossRefPubMed

23.

Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110(9):1690–6.CrossRefPubMed

24.

Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–50.CrossRefPubMed

25.

Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81–7. https://doi.org/10.1007/s00417-007-0660-z.CrossRefPubMed

26.

Lu H, Cui J, Dong H, et al. Clinical observation of a new anti-VEGF drugs conbercept for wet age-related macular degeneration. Chinese J Ophthalmol. 2015;51(11):818–21.

27.

Zhang M, Zhang J, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovascularization in monkeys. Mol Vis. 2008;10(4):37–49.

28.

Steel DH, Habib MS, Park S, Hildreth AJ, Owen RI. The predictive value of inner sclerostomy site ultrasonography. Ophthalmology. 2008;115(3):525–32. https://doi.org/10.1016/j.ophtha.2007.08.034.CrossRefPubMed

29.

Steel DH, Connor A, Habib MS, Owen R. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2010;94(9):1219–25. https://doi.org/10.1136/bjo.2009.170126.CrossRefPubMed

30.

Funatsu H, Yamashita H, Mimura T, Noma H, Nakamura S, Hori S. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye. 2007;21:377–82. https://doi.org/10.1038/sj.eye.6702213.CrossRefPubMed

31.

Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complicat. 2012;26(5):435–41. https://doi.org/10.1016/j.jdiacomp.2012.05.005.CrossRef

32.

Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012;37(5):416–20. https://doi.org/10.3109/02713683.2012.661114.CrossRefPubMed

33.

Cui JZ, Chiu A, Maberley D, et al. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond). 2007;21(2):200–8. https://doi.org/10.1038/sj.eye.6702169.CrossRef

34.

Suganami E, Takagi H, Ohashi H, et al. Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes. 2004;53(9):2443–8.CrossRefPubMed

35.

Hueber A, Wiedemann P, Esser P, Heimann K. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int Ophthalmol. 1996–1997;20(6):345–50. https://doi.org/10.1007/BF00176889.CrossRefPubMed

36.

Wakabayashi Y, Usui Y, Okunuki Y, et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012;53(10):6403–10. https://doi.org/10.1167/iovs.12-10367.CrossRefPubMed

37.

Funatsu H, Yamashita H, Mimura T, et al. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye (Lond). 2007;21(3):377–82. https://doi.org/10.1038/sj.eye.6702213.CrossRef

38.

Funatsu H, Yamashita H, Noma H, et al. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. Br J Ophthalmol. 2004;88(8):1064–8. https://doi.org/10.1136/bjo.2003.032656.CrossRefPubMedPubMedCentral

39.

Zhao X, Yang G, Yang J, Zhang J. Effect of intravitreal conbercept vs triamcinolone acetonide at the end of surgery on macular structure and function in patients with severe proliferative diabetic retinopathy. Int J Clin Exp Med. 2017;10(10):14511–8.

Title: The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study
Authors: Tingting Jiang
Junxiang Gu
Peijun Zhang
Wenwen Chen
Qing Chang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Diabetic Retinopathy
Edema
Diabetic Retinopathy
Vitrectomy
Published in: BMC Ophthalmology / Issue 1/2020
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-020-1321-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study

Abstract

Background

Methods

Results

Conclusions

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

In vivo ultraosound elastographic evaluation of the age-related change of human lens nuclear stiffness

Late intraocular Lens dislocation following scleral depression: a case report

A case of bilateral acute depigmentation of the Iris in one of two identical twins

Spontaneous rotation of a toric implantable collamer lens related to abnormal ciliary body morphology: a case report

A case report of optic neuropathy following dacryocystorhinostomy in a 57-year-old female patient with May-Hegglin anomaly

Clinical implications of pachyvessels in polypoidal choroidal vasculopathy